医学
肝硬化
胃肠病学
内科学
瞬态弹性成像
纤维化
临床终点
安慰剂
肝活检
脂肪变性
代理终结点
脂肪性肝炎
肝病
肝纤维化
脂肪肝
随机对照试验
活检
病理
疾病
替代医学
作者
Rohit Loomba,Mazen Noureddin,Kris V. Kowdley,Anita Kohli,Aasim Sheikh,Guy Neff,Bal Raj Bhandari,Nadege Gunn,Stephen H. Caldwell,Zachary Goodman,Ilan Wapinski,Murray B. Resnick,Andrew H. Beck,Dora Ding,Catherine Jia,Jen‐Chieh Chuang,Ryan S. Huss,Chuhan Chung,G. Mani Subramanian,Robert P. Myers
出处
期刊：Hepatology
[Lippincott Williams & Wilkins]
日期：2020-11-10
卷期号：73 (2): 625-643
被引量：261
摘要
In patients with bridging fibrosis and cirrhosis, 48 weeks of cilofexor/firsocostat was well tolerated, led to improvements in NASH activity, and may have an antifibrotic effect. This combination offers potential for fibrosis regression with longer-term therapy in patients with advanced fibrosis attributable to NASH.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
识字岭的岭
大力的灵雁
无极微光
tiptip
科研狗
Singularity
eric888
nn
蓝莓橘子酱
Dean
HH
pluto
寻道图强
penxyy
bjbmtxy
Twonej
8R60d8
求助人员
殷勤的紫槐
唐美鸭
皖公网安备34019202002308
